Evaluation of an Early Step-Down Strategy From Intravenous Anidulafungin to Oral Azole Therapy for the Treatment of Candidemia and Other Forms of Invasive Candidiasis: Results From an Open-Label Trial

BMC Infectious Diseases - United Kingdom
doi 10.1186/1471-2334-14-97
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pin49 - The Cost-Effectiveness Analysis of Anidulafungin Versus Caspofungin for Candidemia and Invasive Candidiasis Treatment: An Experience From Iran

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Anidulafungin for Candidemia/Invasive Candidiasis in Non-Neutropenic ICU Patients

Critical Care
Critical CareIntensive Care Medicine
2011English

Anidulafungin Versus Fluconazole for Invasive Candidiasis

New England Journal of Medicine
Medicine
2007English

Treatment and Prophylaxis of Invasive Candidiasis With Anidulafungin, Caspofungin and Micafungin - Review of the Literature

European Journal of Medical Research
Medicine
2011English

Re-Treatment of Relapsed Paget's Disease of Bone With Zoledronic Acid: Results From an Open-Label Study

BoneKEy Reports
2013English

Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Preliminary Results of an Open-Label Non-Randomized Clinical Trial

2020English

Bilateral Intra-Articular Injection of CNTX-4975 for Management of Painful Osteoarthritis of the Knee: Results at 6 Weeks From an Open-Label Trial

Osteoarthritis and Cartilage
Sports MedicineRheumatologyOrthopedicsBiomedical Engineering
2019English

An Azole-Tolerant Endosomal Trafficking Mutant of Candida Albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression

American Journal of Psychiatry
PsychiatryMental Health
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy